Drugs Made In America Acquisition Corp.
DMAAR- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002028614
No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $1.30M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 28
- 13F valueReported value at the end of Q2 2026
- $1.30M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DMAAR, Q2 2026
No superinvestor reported holding DMAAR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Drugs Made In America Acquisition Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 (view filing) | Feb 18 | Same day | Drugs Made In America Acquisition LLC10% Owner | PPurchase | +30.0K | – | – | +0.7%4.19M after | Duplicate filing |
| Feb 18, 2025 (view filing) | Feb 18 | Same day | Drugs Made In America Acquisition LLC10% Owner | PPurchase | +30.0K | – | – | –430.0K after | DerivativeDuplicate filing |
| Feb 18, 2025 (view filing) | Feb 18 | Same day | Stockwell LynnCEO and Exe. Chair of Board | PPurchase | +30.0K | – | – | +0.7%4.19M after | |
| Feb 18, 2025 (view filing) | Feb 18 | Same day | Stockwell LynnCEO and Exe. Chair of Board | PPurchase | +30.0K | – | – | –430.0K after | Derivative |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Drugs Made In America Acquisition LLC10% Owner | PPurchase | +400.0K | – | – | +4.1%10.3M after | |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Drugs Made In America Acquisition LLC10% Owner | SSale | −5.70M | – | – | −57.8%4.16M after | Duplicate filing |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Drugs Made In America Acquisition LLC10% Owner | PPurchase | +400.0K | – | – | –400.0K after | DerivativeDuplicate filing |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Stockwell LynnCEO and Executive COB | PPurchase | +400.0K | – | – | New position10.3K after | |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Stockwell LynnCEO and Executive COB | SSale | −5.70M | – | – | −57.8%4.16M after | |
| Feb 4, 2025 (view filing) | Jan 29 | 6 daysLate | Stockwell LynnCEO and Executive COB | PPurchase | +400.0K | – | – | –400.0K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Drugs Made In America Acquisition Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 1,900,000 | $209.0K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 850,000 | $97.8K | 0.00% | 00.0% | Unchanged |
| Mangrove Partners | 850,000 | $93.5K | 0.01% | 00.0% | Unchanged |
| Toronto Dominion Bank | 800,000 | $88.0K | 0.00% | +110,000+15.9% | Added |
| Hudson Bay Capital Management LP | 758,719 | $83.5K | 0.00% | −942,827−55.4% | Reduced |
| Clear Street Group Inc. | 711,088 | $78.2K | 0.00% | −829−0.1% | Reduced |
| Highbridge Capital Management LLC | 857,493 | $77.3K | 0.00% | −186,826−17.9% | Reduced |
| Rivernorth Capital Management, LLC | 417,998 | $62.7K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 529,898 | $58.3K | 0.00% | −165,329−23.8% | Reduced |
| LMR Partners LLP | 500,000 | $55.0K | 0.00% | 00.0% | Unchanged |